MX372990B - Composiciones para el tratamiento del ojo seco. - Google Patents

Composiciones para el tratamiento del ojo seco.

Info

Publication number
MX372990B
MX372990B MX2014004203A MX2014004203A MX372990B MX 372990 B MX372990 B MX 372990B MX 2014004203 A MX2014004203 A MX 2014004203A MX 2014004203 A MX2014004203 A MX 2014004203A MX 372990 B MX372990 B MX 372990B
Authority
MX
Mexico
Prior art keywords
dry eye
compositions
treatment
treat
diagnose
Prior art date
Application number
MX2014004203A
Other languages
English (en)
Other versions
MX2014004203A (es
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47040830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX372990(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2014004203A publication Critical patent/MX2014004203A/es
Publication of MX372990B publication Critical patent/MX372990B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a composiciones oftálmicas y métodos útiles para tratar el ojo seco, o para diagnosticar, curar, aliviar, tratar o evitar el síndrome del ojo seco en el hombre y otros animales.
MX2014004203A 2011-10-06 2012-10-05 Composiciones para el tratamiento del ojo seco. MX372990B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544151P 2011-10-06 2011-10-06
PCT/US2012/058893 WO2013052760A1 (en) 2011-10-06 2012-10-05 Compositions for the treatment of dry eye

Publications (2)

Publication Number Publication Date
MX2014004203A MX2014004203A (es) 2014-10-17
MX372990B true MX372990B (es) 2020-04-28

Family

ID=47040830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004203A MX372990B (es) 2011-10-06 2012-10-05 Composiciones para el tratamiento del ojo seco.

Country Status (18)

Country Link
US (8) US8957048B2 (es)
EP (1) EP2765987A1 (es)
JP (1) JP6209163B2 (es)
CN (2) CN103974694A (es)
AU (1) AU2012318556B2 (es)
BR (1) BR112014008314B1 (es)
CA (1) CA2851398C (es)
CL (1) CL2014000863A1 (es)
HK (1) HK1201042A1 (es)
IL (1) IL231970A (es)
MX (1) MX372990B (es)
MY (1) MY169328A (es)
PH (1) PH12014500767A1 (es)
RU (1) RU2651046C2 (es)
SG (1) SG11201401323PA (es)
TW (1) TWI642432B (es)
WO (1) WO2013052760A1 (es)
ZA (1) ZA201404121B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PT2787969T (pt) 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
CA2967413C (en) * 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
AU2016246060B2 (en) 2015-04-10 2020-10-22 Bausch + Lomb Ireland Limited Piezoelectric dispenser with replaceable ampoule
CN105311042B (zh) * 2015-09-07 2019-04-12 广州国宇医药科技有限公司 一种糖醇组合物在制备治疗干眼症的药物中的应用
WO2017116826A1 (en) * 2015-12-28 2017-07-06 Indiana University Research And Technology Corporation Identification of contact lens wearers predisposed to contact lens discomfort
CA3032695C (en) 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
US10888454B2 (en) 2017-01-20 2021-01-12 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
JP7311160B2 (ja) * 2017-08-18 2023-07-19 アクリビスタ エルエルシー ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物
WO2019054491A1 (ja) * 2017-09-14 2019-03-21 協同乳業株式会社 涙液分泌能・涙液安定性を改善するための飲食品または製剤
AU2018380433B2 (en) 2017-12-08 2024-10-10 Bausch + Lomb Ireland Limited Fluid delivery alignment system
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314198A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
AU2019297326B2 (en) 2018-07-03 2025-01-09 Bausch + Lomb Ireland Limited Topical ocular delivery devices and methods for using the same
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
JP7739316B2 (ja) * 2020-03-12 2025-09-16 レッドウッド ファーマ アクティエボラーグ 治療の新しい使用及び方法
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
BR112022020948A2 (pt) 2020-04-17 2023-04-11 Kedallion Therapeutics Inc Sistema de distribuição livre de conservantes hidrodinamicamente atuado
WO2022103775A1 (en) 2020-11-12 2022-05-19 Singletto Inc. Microbial disinfection for personal protection equipment
WO2022156371A1 (zh) * 2021-01-22 2022-07-28 成都瑞沐生物医药科技有限公司 一种眼用制剂的载体或辅料及其制备方法和应用
US12397017B2 (en) 2022-01-12 2025-08-26 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
CN114533582B (zh) * 2022-02-25 2023-05-09 北京协和生物工程研究所有限公司 一种包含多种渗透压保护剂的眼周用组合物
US12359369B2 (en) 2022-08-11 2025-07-15 Singletto Inc. Skin protection against microbial particles
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE69004066T2 (de) 1989-08-03 1994-02-17 Eisai Co Ltd Verfahren zur photostabilisierung von augenspüllösungen.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AU3484895A (en) 1994-09-14 1996-03-29 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing corneal disturbance
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
DE19859910C2 (de) 1998-12-23 2001-03-22 Ratiopharm Gmbh Orales Arzneimittel
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
HU230383B1 (hu) 2000-07-14 2016-03-29 Allergan, Inc Oldékonyságfokozó komponens használata brimodinin-tartarátot tartalmazó vizes készítményekben
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
US9492581B2 (en) 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CA2572344A1 (en) * 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
EP1858522A4 (en) * 2005-03-02 2008-07-16 Pharmaceutical Inc Nascent PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
JP2010520210A (ja) * 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
CA2741288A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
PL2437762T3 (pl) * 2009-06-05 2018-01-31 Allergan Inc Sztuczne łzy i ich zastosowania terapeutyczne
HUE038789T2 (hu) 2009-10-07 2018-11-28 Kerecis Ehf Vázanyag sebkezelésre és/vagy sebgyógyításban történõ alkalmazásra
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787969T (pt) * 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal

Also Published As

Publication number Publication date
RU2651046C2 (ru) 2018-04-18
IL231970A0 (en) 2014-05-28
MX2014004203A (es) 2014-10-17
AU2012318556B2 (en) 2017-10-26
CN108175778B (zh) 2024-07-05
JP6209163B2 (ja) 2017-10-04
IL231970A (en) 2016-12-29
US20140242022A1 (en) 2014-08-28
BR112014008314A2 (pt) 2017-04-11
ZA201404121B (en) 2016-07-27
RU2014122945A (ru) 2015-12-20
US10105386B2 (en) 2018-10-23
CA2851398A1 (en) 2013-04-11
US20220096523A1 (en) 2022-03-31
WO2013052760A1 (en) 2013-04-11
US20250281521A1 (en) 2025-09-11
MY169328A (en) 2019-03-21
BR112014008314B1 (pt) 2022-04-05
US20190247419A1 (en) 2019-08-15
EP2765987A1 (en) 2014-08-20
US20210000859A1 (en) 2021-01-07
SG11201401323PA (en) 2014-08-28
CA2851398C (en) 2019-11-05
CN108175778A (zh) 2018-06-19
US8957048B2 (en) 2015-02-17
TW201316984A (zh) 2013-05-01
TWI642432B (zh) 2018-12-01
PH12014500767A1 (en) 2015-10-23
JP2014528452A (ja) 2014-10-27
US20150196582A1 (en) 2015-07-16
CN103974694A (zh) 2014-08-06
HK1201042A1 (en) 2015-08-21
CL2014000863A1 (es) 2014-08-29
US20240122963A1 (en) 2024-04-18
NZ625799A (en) 2016-09-30
AU2012318556A1 (en) 2014-07-31
US20130090308A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
MX372990B (es) Composiciones para el tratamiento del ojo seco.
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
CO7000769A2 (es) Composiciones y métodos para el tratamiento de presbicia, hipermetropía leve, y astigmatismo irregular
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
JO3564B1 (ar) ببتيدات وتركيبات لعلاج ضرر المفاصل
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
MX2016009898A (es) Tratamientos para acne resistente.
BR112017006664A2 (pt) terapias de combinação
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
MX2019006893A (es) Inhibidores heterociclicos de mct4.
MX2015003701A (es) Composiciones para tratamiento.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
ECSP14011792A (es) Inhibidores de iap
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX385774B (es) Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας
HK1202440A1 (zh) 用於治療缺血性損傷的半胱胺和/或胱胺

Legal Events

Date Code Title Description
FG Grant or registration